tert.-Butyl-glyoxylsaeure-N-isopropyl-amid | 95112-92-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: tert.-Butyl-glyoxylsaeure-N-isopropyl-amid
• 英文别名: N-isopropyl-3,3-dimethyl-2-oxobutanamide；3,3-dimethyl-2-oxo-N-propan-2-ylbutanamide
• CAS: 95112-92-8
• 化学式: C₉H₁₇NO₂
• 分子量: 171.239
• InChiKey: CQQSCHYPQJTNIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  三甲基乙酰氯 在 水 作用下， 生成 tert.-Butyl-glyoxylsaeure-N-isopropyl-amid
  参考文献：
  名称：

  Ugi,I.; Fetzer,U., Chemische Berichte, 1961, vol. 94, p. 1116 - 1121

  摘要：

  DOI：

文献信息

• High yield acyl anion trapping reactions: direct nucleophilic acylation of isocyanates and isothiocyanates.
  作者：Dietmar Seyferth、Richard C. Hui

  DOI：10.1016/s0040-4039(01)81576-8

  日期：——

  The reactions of t-BuLi, sec-BuLi and n-BuLi with CO in the presence of isothiocyanates and isocyanates gives, after hydrolytic work-up, α-oxothioamides, RC(O)C(S)NHR′, and α-oxoamides, RC(O)C(O)NHR′, respectively, in good yield. Competition from the direct reaction of RLi with the substrate is encountered only in the case of reactions of the n-BuLi/CO system with isocyanates.

  在异硫氰酸酯和异氰酸酯的存在下，t-BuLi，sec-BuLi和n-BuLi与CO的反应在水解后处理后得到α-氧代硫代酰胺，RC（O）C（S）NHR'和α-氧代酰胺，RC（O）C（O）NHR'的收率很高。仅在n-BuLi / CO系统与异氰酸酯反应的情况下，才会遇到RLi与底物直接反应的竞争。
• Inhibitors of serine proteases, particular HCV NS3-NS4A protease
  申请人：Pitlik Janos

  公开号：US20070292933A1

  公开（公告）日：2007-12-20

  The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及抑制丝氨酸蛋白酶活性的化合物，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰乙型肝炎病毒的生命周期而起作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于治疗患有HCV感染的患者的给药。本发明还涉及通过给予含有本发明化合物的组合物来治疗患有HCV感染的患者的方法。本发明还涉及制备这些化合物的过程。
• INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
  申请人：Cottrell Kevin M.

  公开号：US20090291902A1

  公开（公告）日：2009-11-26

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

  本发明涉及化合物I的公式：或其药学上可接受的盐，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰丙型肝炎病毒的生命周期发挥作用，并且可用作抗病毒剂。本发明还涉及药学上可接受的组合物，包括上述化合物，用于体外使用或用于治疗患有HCV感染的患者，并且涉及制备该化合物的过程。本发明还涉及通过给患者注射本发明的化合物的药物组合物来治疗HCV感染的方法。
• SEYFERTH, D.;HUI, R. C., TETRAHEDRON LETT., 1984, 25, N 46, 5251-5254
  作者：SEYFERTH, D.、HUI, R. C.

  DOI：——

  日期：——
• NOVEL COMPOUNDS AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2
  申请人：UNIVERSITÉ DE PARIS

  公开号：US20200317647A1

  公开（公告）日：2020-10-08

  The present invention relates to a compound of formula (I): wherein P 1 , P 3 , P 4 and P 5 are amino acid residues or amino acid like structures. The invention also relates to a compound of formula (I) for its use as a Caspase-2 inhibitor and for its therapeutical use. It also concerns the use of a compound of formula (I) as activity base probe to selectively detect Caspase-2 activity.